Medpace Holdings, Inc.

Previous wording

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, with our audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and with the information under the heading “Management Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. This item and the related discussion contain forward-looking statements reflecting current expectations that involve risks and uncertainties. Actual results and the timing of events may differ materially from those indicated in such forward-looking statements. Important factors that may cause such differences include, but are not limited to, those discussed under the “Forward-Looking Statements” below and “Risk Factors” in “Item 1A Risk Factors” of Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Current wording

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, with our audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and with the information under the heading “Management Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. This item and the related discussion contain forward-looking statements reflecting current expectations that involve risks and uncertainties. Actual results and the timing of events may differ materially from those indicated in such forward-looking statements. Factors that may cause such differences include, but are not limited to, those discussed under the “Forward-Looking Statements” below and “Risk Factors” in “Item 1A Risk Factors” of Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Previous wording

This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts contained herein, are forward looking statements. Forward looking statements include, without limitation, statements regarding our results of operations; financial position and performance; liquidity and our ability to fund our business operations and initiatives; capital expenditure and debt service obligations; business strategies, plans and goals, including those related to marketing, acquisitions and expansion of our business; product approvals and plans; industry trends; general economic conditions, including inflation, interest rates and other pricing pressures that could impact our operating margins; expectations regarding consumer behaviors and trends; our culture and operating philosophy; human resource management; arrangements with and delivery of our services to the customers; conversion of backlog; dividend policy; legal proceedings; and our objectives for future operations. The words “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” “likely,” “opportunity,” “may,” “could,” “outlook,” “can,” “trend,” “might,” “drives,” “hope,” “potential,” “project,” “predict,” and similar expressions are intended to identify forward-looking statements. However, the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based largely on our current expectations and projections about future events and financial or other trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Any forward-looking statement speaks only as of the date it is made. These forward-looking statements are subject to inherent uncertainties, risks, changes in circumstances and other important factors that are difficult to predict. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all important factors on our business or the extent to which any factor, or combination of such factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed may not occur and our financial condition and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In other words, these statements are not guarantees of future performance and inhe…

Excerpt shortened here; the source contains the full paragraph.

Current wording

This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts contained herein, are forward looking statements. Forward looking statements include, without limitation, statements regarding our results of operations; financial position and performance; liquidity and our ability to fund our business operations and initiatives; capital expenditure and debt service obligations; business strategies, plans and goals, including those related to marketing, acquisitions and expansion of our business; product approvals and plans; industry trends; general economic conditions, including inflation, interest rates and other pricing pressures that could impact our operating margins; expectations regarding consumer behaviors and trends; our culture and operating philosophy; human resource management; arrangements with and delivery of our services to the customers; conversion of backlog; dividend policy; legal proceedings; and our objectives for future operations. The words “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” “likely,” “opportunity,” “may,” “could,” “outlook,” “can,” “trend,” “might,” “drives,” “hope,” “potential,” “project,” “predict,” and similar expressions are intended to identify forward-looking statements. However, the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based largely on our current expectations and projections about future events and financial or other trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Any forward-looking statement speaks only as of the date it is made. These forward-looking statements are subject to inherent uncertainties, risks, changes in circumstances and other factors that are difficult to predict. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of such factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed may not occur and our financial condition and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In other words, these statements are not guarantees of future performance and inherently involve a wid…

Excerpt shortened here; the source contains the full paragraph.

Previous wording

We are one of the world’s leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Our mission is to accelerate the global development of safe and effective medical therapeutics. We differentiate ourselves from our competitors by our disciplined operating model centered on providing full-service Phase I-IV clinical development services and our therapeutic expertise. We believe this combination results in timely and cost-effective delivery of clinical development services for our customers. We believe that we are a partner of choice for small-

Current wording

We are one of the world’s leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Our mission is to accelerate the global development of safe and effective medical therapeutics. We differentiate ourselves from our competitors by our disciplined operating model centered on providing full-service Phase I-IV clinical development services and our therapeutic expertise. We believe this combination results in timely and cost-

Previous wording

-19- and mid-sized biopharmaceutical companies based on our ability to consistently utilize our full-service, disciplined operating model to deliver timely and high-quality results for our customers.

Current wording

-19- effective delivery of clinical development services for our customers. We believe that we are a partner of choice for small- and mid-sized biopharmaceutical companies based on our ability to consistently utilize our full-service, disciplined operating model to deliver timely and high-quality results for our customers.

Previous wording

We focus on conducting clinical trials across all major therapeutic areas, with particular strength in Oncology, Metabolic Disease, Cardiology, Central Nervous System, or CNS, and Antiviral and Anti-infective, or AVAI. Our global platform includes approximately 5,900 employees across 44 countries as of March 31, 2025, providing our customers with broad access to diverse markets and patient populations as well as local regulatory expertise and market knowledge.

Current wording

We focus on conducting clinical trials across all major therapeutic areas, with particular strength in Oncology, Metabolic Disease, Cardiology, Central Nervous System, or CNS, and Antiviral and Anti-infective, or AVAI. Our global platform includes approximately 6,000 employees across 44 countries as of June 30, 2025, providing our customers with broad access to diverse markets and patient populations as well as local regulatory expertise and market knowledge.

Previous wording

Depreciation is provided on our property and equipment on the straight-line method at rates adequate to allocate the cost of the applicable assets over their estimated useful lives, which is three to five years for computer hardware, software, phone, and medical imaging equipment, five to seven years for furniture and fixtures and other equipment, and thirty to forty years

Current wording

Depreciation is provided on our property and equipment on the straight-line method at rates adequate to allocate the cost of the applicable assets over their estimated useful lives, which is three to five years for computer hardware, software, phone,

Previous wording

-20- for buildings. Leasehold improvements are amortized on a straight-line basis over the shorter of the estimated useful life of the improvement or the associated remaining lease term.

Current wording

-20- and medical imaging equipment, five to seven years for furniture and fixtures and other equipment, and thirty to forty years for buildings. Leasehold improvements are amortized on a straight-line basis over the shorter of the estimated useful life of the improvement or the associated remaining lease term.

Previous wording

Net new business awards represent gross new business awards received in a period offset by total cancellations in that period. Net new business awards were $500.0 million and $615.6 million for the three months ended March 31, 2025 and 2024, respectively.

Current wording

Net new business awards represent gross new business awards received in a period offset by total cancellations in that period. Net new business awards were $620.5 million and $1,120.6 million for the three and six months ended June 30, 2025, respectively. Net new business awards were $551.0 million and $1,166.5 million for the three and six months ended June 30, 2024, respectively.

Previous wording

Backlog represents anticipated future net revenue from net new business awards that have not commenced or are currently in process but not complete. Reported backlog will fluctuate based on new business awards, changes in the scope of existing contracts, cancellations, revenue recognition on existing contracts and foreign exchange adjustments from non-U.S. dollar denominated backlog. As of March 31, 2025, our backlog decreased by $61.1 million, or 2.1%, to $2,846.0 million compared to $2,907.1 million as of March 31, 2024. Included within backlog as of March 31, 2025 was approximately $1,600.0 million to $1,620.0 million that we expect to convert to net revenue over the next twelve months, with the remainder expected to convert to net revenue thereafter.

Current wording

Backlog represents anticipated future net revenue from net new business awards that have not commenced or are currently in process but not complete. Reported backlog will fluctuate based on new business awards, changes in the scope of existing contracts, cancellations, revenue recognition on existing contracts and foreign exchange adjustments from non-U.S. dollar denominated backlog. As of June 30, 2025, our backlog decreased by $51.3 million, or 1.8%, to $2,873.6 million compared to $2,924.9 million as of June 30, 2024. Included within backlog as of June 30, 2025 was approximately $1,740.0 million to $1,760.0 million that we expect to convert to net revenue over the next twelve months, with the remainder expected to convert to net revenue thereafter.

Previous wording

The effect of foreign currency adjustments on backlog was as follows: favorable foreign currency adjustments of $6.9 million for the three months ended March 31, 2025 and unfavorable foreign currency adjustments of $6.8 million for the three months ended March 31, 2024.

Current wording

The effect of foreign currency adjustments on backlog was as follows: favorable foreign currency adjustments of $14.5 million for the three months ended June 30, 2025; favorable foreign currency adjustments of $21.4 million for the six months ended June 30, 2025; unfavorable foreign currency adjustments of $1.2 million for the three months ended June 30, 2024; and unfavorable foreign currency adjustments of $8.0 million for the six months ended June 30, 2024.

Previous wording

Total revenue increased by $47.5 million, to $558.6 million for the three months ended March 31, 2025, from $511.0 million for the three months ended March 31, 2024. The increase for the three months ended March 31, 2025 was primarily driven by growth within the Metabolic, Oncology, and Central Nervous System therapeutic areas, compared to the same period in the prior year.

Current wording

Total revenue increased by $75.2 million to $603.3 million for the three months ended June 30, 2025, from $528.1 million for the three months ended June 30, 2024. Total revenue increased by $122.7 million to $1,161.9 million for the six months ended June 30, 2025, from $1,039.1 million for the six months ended June 30, 2024. The increase for the three and six months ended June 30, 2025 was primarily driven by growth within the Metabolic, Oncology and Central Nervous System therapeutic areas, compared to the same periods in the prior year.

Previous wording

Total direct costs increased by $24.3 million, to $380.2 million for the three months ended March 31, 2025, from $355.9 million for the three months ended March 31, 2024. The increase was primarily attributed to higher reimbursed out-of-pocket expenses and higher personnel costs to support the growth in service activities. Reimbursed out-of-pocket expenses, which can fluctuate significantly from period to period based on the timing of program initiation and closeout, increased $18.0 million for the three months ended March 31, 2025, compared to the same period in the prior year. The higher personnel costs portion increased by $5.4 million for the three months ended March 31, 2025, compared to the same period in the prior year.

Current wording

Total direct costs increased by $49.0 million, to $423.3 million for the three months ended June 30, 2025 from $374.3 million for the three months ended June 30, 2024. Total direct costs increased by $73.4 million, to $803.5 million for the six months ended June 30, 2025 from $730.2 million for the six months ended June 30, 2024. The increase was primarily attributed to higher reimbursed out-of-pocket expenses and higher personnel costs to support the growth in service activities. Reimbursed out-of-pocket expenses, which can fluctuate significantly from period to period based on the timing of program initiation and closeout, increased by $34.7 million and $52.7 million for the three and six months ended June 30, 2025, compared to the same periods in the prior year. The higher personnel costs portion increased by $12.0 million and $17.4 million for the three and six months ended June 30, 2025, compared to the same periods in the prior year.

Previous wording

Selling, general and administrative expenses increased by $13.8 million, to $57.9 million for the three months ended March 31, 2025, from $44.1 million for the three months ended March 31, 2024. The increase was primarily attributed to higher personnel costs to support the growth in service activities. The higher personnel costs portion increased by $14.6 million for the three months ended March 31, 2025, compared to the same period in the prior year.

Current wording

Selling, general and administrative expenses increased by $5.2 million, to $46.7 million for the three months ended June 30, 2025 from $41.5 million for the three months ended June 30, 2024. Selling, general and administrative expenses increased by $19.0 million, to $104.6 million for the six months ended June 30, 2025 from $85.5 million for the six months ended June 30, 2024. The increase was primarily attributed to higher personnel costs to support the growth in service activities. The higher personnel costs portion increased by $4.4 million and $19.0 million for the three and six months ended June 30, 2025, compared to the same periods in the prior year.

Previous wording

Depreciation and amortization expense of $6.9 million for the three months ended March 31, 2025, remained relatively consistent with $7.0 million for the three months ended March 31, 2024.

Current wording

Depreciation and amortization expense of $7.0 million for the three months ended June 30, 2025, remained relatively consistent with $7.2 million for the three months ended June 30, 2024. Depreciation and amortization expense of $13.9 million for the six months ended June 30, 2025, remained relatively consistent with $14.2 million for the six months ended June 30, 2024.

Previous wording

Miscellaneous (expense) income, net changed by $6.4 million, to $1.8 million of expense for the three months ended March 31, 2025, from $4.6 million of income for the three months ended March 31, 2024. The change was mainly attributable to foreign exchange gains and losses that arise in connection with the revaluation of short-term intercompany balances between our domestic and international subsidiaries, gains or losses from foreign currency transactions, such as those resulting from the settlement of third-party accounts receivables and payables denominated in a currency other than the local currency of the entity making the payment and proceeds from the recovery of a note receivable, compared to the same period in the prior year.

Current wording

Miscellaneous expense, net increased by $2.7 million to $2.9 million for the three months ended June 30, 2025, from $0.1 million for the three months ended June 30, 2024. Miscellaneous (expense) income, net changed by $9.2 million to $4.7 million of expense for the six months ended June 30, 2025 from $4.5 million of income for the six months ended June 30, 2024. These changes were mainly attributable to foreign exchange gains and losses that arise in connection with the revaluation of short-term intercompany balances between our domestic and international subsidiaries and from the settlement of third-party accounts receivables and payables denominated in a currency other than the local currency of the entity making the payment, third-party investment gains or losses and proceeds from the recovery of a note receivable, compared to the same periods in the prior year.

Previous wording

Interest income, net increased by $2.3 million, to $6.5 million for the three months ended March 31, 2025, from $4.1 million for the three months ended March 31, 2024. This change was mainly attributable to increased interest income on Cash and cash equivalents, compared to the same period in the prior year.

Current wording

Interest income, net decreased by $4.4 million to $1.1 million for the three months ended June 30, 2025, from $5.5 million for the three months ended June 30, 2024. Interest income, net decreased by $2.0 million to $7.5 million for the six months ended June 30, 2025, from $9.6 million for the six months ended June 30, 2024. These changes were mainly attributable to decreased interest income on Cash and cash equivalents, compared to the same periods in the prior year.

Previous wording

Income tax provision decreased by $6.6 million, to $3.6 million for the three months ended March 31, 2025, from $10.2 million for the three months ended March 31, 2024. The overall effective tax rate for the three months ended March 31, 2025 was 3.0%, compared to an overall effective tax rate of 9.0% for the three months ended March 31, 2024. The decrease in the income tax provision was primarily attributable to an increase in excess tax benefits recognized from share-based compensation, which was partially offset by an increase in pre-tax book income compared to the same period in the prior year. The decrease in the overall effective tax rate was primarily attributable to an increase in excess tax benefits recognized from share-based compensation compared to the same period in the prior year.

Current wording

Income tax provision increased by $12.1 million, to $34.3 million for the three months ended June 30, 2025 from $22.1 million for the three months ended June 30, 2024. Income tax provision increased by $5.5 million, to $37.9 million for the six months ended June 30, 2025 from $32.3 million for the six months ended June 30, 2024. The overall effective tax rate for the three months ended June 30, 2025 was 27.5%, compared to an overall effective tax rate of 20.0% for the three months ended June 30, 2024. The overall effective tax rate for the six months ended June 30, 2025 was 15.6% compared to an overall effective tax rate of 14.5% for the six months ended June 30, 2024. The increase in the income tax provision and overall effective tax rate for the three months ended June 30, 2025 was primarily attributable to an increase in pre-tax book income, a decrease in excess tax benefits recognized from share-based compensation and a decrease in the estimated tax benefits related to Foreign Derived Intangible Income (FDII) compared to the same period in the prior year. The increase in the income tax provision and overall effective tax rate for the six months ended June 30, 2025 was primarily attributable to an increase in pre-tax book income and a decrease in the estimated tax benefits related to FDII, which was partially offset by an increase in excess tax benefits recognized from share-based compensation compared to the same period in the prior year.

Previous wording

We assess our liquidity in terms of our ability to generate cash to fund our operating, investing and financing activities. Our principal sources of liquidity as of March 31, 2025 are operating cash flows and from borrowings under our unsecured credit facility consisting of up to a $10.0 million revolving line of credit which we entered into on September 30, 2019 (the “Credit Facility”), and has subsequently been amended. As of March 31, 2025, we had cash and cash equivalents of $441.4 million which decreased from $669.4 million as of December 31, 2024. Approximately $40.4 million of cash and cash equivalents, none of which was restricted, was held by our foreign subsidiaries as of March 31, 2025.

Current wording

We assess our liquidity in terms of our ability to generate cash to fund our operating, investing and financing activities. Our principal sources of liquidity as of June 30, 2025 are operating cash flows and from borrowings under our unsecured credit facility consisting of up to a $600.0 million revolving line of credit which we entered into on September 30, 2019 (the “Credit Facility”), and has subsequently been amended. As of June 30, 2025, we had cash and cash equivalents of $46.3 million which decreased from $669.4 million as of December 31, 2024 primarily due to repurchases of common stock. Approximately $23.1 million of cash and cash equivalents, none of which was restricted, was held by our foreign subsidiaries as of June 30, 2025.

Previous wording

As of March 31, 2025, we had $10.0 million available for borrowing under the Credit Facility. On April 18, 2025, the Company entered into Amendment No. 8 to the Loan Agreement, which increased the aggregate principal amount that may be borrowed under the facility’s line of credit to up to $600.0 million, adjusted the interest rate charged on the credit facility and extended the expiration date of revolving credit note to April 30, 2027. Our expected primary cash needs on both a short and long-term basis are for investment in operational growth, including additional lease commitments, capital expenditures, share repurchases, selective strategic bolt-on acquisitions, other investments, and other general corporate needs. We have historically funded our operations and growth with cash flow from operations and borrowings under our credit facilities. We expect to continue expanding our operations through organic growth and potentially highly selective bolt-on acquisitions and investments. As of March 31, 2025, cash commitments to support operating business needs include lease liabilities discussed in Note 8 of the Condensed Consolidated Financial Statements, purchase commitments discussed in Note 11 of the Condensed Consolidated Financial Statements and capital expenditures primarily related to infrastructure investments in our facilities, equipment and technology. Capital spending as a percentage of revenue increased by 71 basis points to 1.79% in the three months ended March 31, 2025, compared to the same period in the prior year. We expect these activities will be funded from existing cash, cash flow from operations and, if necessary, borrowings under our existing or future credit facilities or other debt. We have deemed that foreign earnings will be indefinitely reinvested and therefore we have not provided taxes on these earnings. While we do not anticipate the need to repatriate these foreign earnings for liquidity purposes given our cash flows from operations and borrowings under existing and future credit facilities, we would incur taxes on these earnings if the need for repatriation due to liquidity purposes arises.

Current wording

As of June 30, 2025, we had $600.0 million available for borrowing under the Credit Facility. On July 17, 2025, the Company entered into Amendment No. 9 to the Loan Agreement, which decreased the aggregate principal amount that may be borrowed under the Credit Facility to up to $10.0 million. Our expected primary cash needs on both a short and long-term basis are for investment in operational growth, including additional lease commitments, capital expenditures, share repurchases, selective strategic bolt-on acquisitions, other investments, and other general corporate needs. We have historically funded our operations and growth with cash flow from operations and borrowings under our credit facilities. We expect to continue expanding our operations through organic growth and potentially highly selective bolt-on acquisitions and investments. As of June 30, 2025, cash commitments to support operating business needs include lease liabilities discussed in Note 8 of the Condensed Consolidated Financial Statements, purchase commitments discussed in Note 11 of the Condensed Consolidated Financial Statements and capital expenditures primarily related to infrastructure investments in our facilities, equipment and technology. Capital spending as a percentage of revenue decreased by 38 basis points to 1.39% in the six months ended June 30, 2025, compared to the same period in the prior year. We expect these activities will be funded from existing cash, cash flow from operations and, if necessary, borrowings under our existing or

Previous wording

Cash flows from operations are driven mainly by net income, stock-based compensation expense, depreciation, noncash lease expense and net movement in advanced billings, accrued expenses and accounts receivable and unbilled, net. Accounts receivable and unbilled, net and advanced billings fluctuate on a regular basis as we perform our services, bill our customers and ultimately collect on those receivables. We attempt to negotiate payment terms in order to provide for payments prior to or soon after the provision of services, but this timing of collection can vary significantly on a period by period comparative basis.

Current wording

Cash flows from operations are driven mainly by net income, deferred income tax provision, stock-based compensation expense, depreciation, noncash lease expense and net movement in advanced billings, accounts receivable and unbilled, net and prepaid expenses and other current assets. Advanced billings and accounts receivable and unbilled, net fluctuate on a regular basis as we perform our services, bill our customers and ultimately collect on those receivables. We attempt to negotiate payment terms in order to provide for payments prior to or soon after the provision of services, but this timing of collection can vary significantly on a period by period comparative basis.

Previous wording

Net cash flows provided by operating activities was $152.7 million for the three months ended March 31, 2024 beginning with net income of $102.6 million. Adjustments to reconcile net income to net cash provided by operating activities were $11.9 million, primarily related to depreciation of $6.6 million, noncash lease expense of $5.7 million and stock based compensation expense of $4.3 million. Changes in operating assets and liabilities provided $38.2 million in operating cash flows and was primarily driven by increased advanced billings of $56.8 million and decreased accounts receivable and unbilled, net of $19.1 million, partially offset by decreased accrued expenses of $21.1 million and increased prepaid expenses and other current assets of $9.2 million.

Current wording

Net cash flows provided by operating activities was $274.4 million for the six months ended June 30, 2025 beginning with net income of $204.9 million. Adjustments to reconcile net income to net cash provided by operating activities were $82.8 million, primarily related to deferred income tax provision of $34.9 million, stock-based compensation expense of $22.8 million, depreciation of $13.5 million and noncash lease expense of $11.7 million. Changes in operating assets and liabilities used $13.3 million in operating cash flows and was primarily driven by increased accounts receivable and unbilled, net of $82.0 million and increased prepaid expenses and other current assets of 33.1 million, partially offset by increased advanced billings of $98.2 million.

Previous wording

Net cash flows provided by operating activities was $125.8 million for the three months ended March 31, 2025 beginning with net income of $114.6 million. Adjustments to reconcile net income to net cash provided by operating activities were $30.1 million, primarily related to stock based compensation expense of $16.9 million, depreciation of $6.7 million and noncash lease expense of $6.1 million. Changes in operating assets and liabilities used $18.9 million in operating cash flows and was primarily driven by decreased accrued expenses of $23.2 million and increased prepaid expenses and other current assets of $17.6 million, partially offset by changes in other assets and liabilities, net of $11.6 million, increased accounts payable of $10.7 million and increased advanced billings of $8.1 million.

Current wording

Net cash flows provided by operating activities was $269.1 million for the six months ended June 30, 2024 beginning with net income of $190.9 million. Adjustments to reconcile net income to net cash provided by operating activities were $28.8 million, primarily related to depreciation of $13.5 million, noncash lease expense of $11.5 million and stock-based compensation expense of $7.9 million. Changes in operating assets and liabilities provided $49.4 million in operating cash flows and was primarily driven by increased advanced billings of $78.6 million, partially offset by increased prepaid expenses and other current assets of $11.3 million and decreased lease liabilities of $11.0 million.

Previous wording

Net cash used in investing activities was $10.0 million for the three months ended March 31, 2025 primarily consisting of property and equipment expenditures.

Current wording

Net cash used in investing activities was $16.0 million for the six months ended June 30, 2025 primarily consisting of property and equipment expenditures.

Previous wording

Net cash provided by investing activities was $2.5 million for the three months ended March 31, 2024 primarily consisting of 8.0 million in other investing activity, partially offset by $5.5 million of property and equipment expenditures.

Current wording

Net cash used in investing activities was $10.3 million for the six months ended June 30, 2024 primarily consisting of property and equipment expenditures of $18.4 million, partially offset by $8.1 million in other investing activity.

Previous wording

Net cash used in financing activities was $346.0 million for the three months ended March 31, 2025 primarily related to $371.9 million in repurchases of common stock, partially offset by proceeds from stock option exercises of $25.9 million.

Current wording

Net cash used in financing activities was $886.5 million for the six months ended June 30, 2025 primarily related to $912.8 million in repurchases of common stock, partially offset by proceeds from stock option exercises of $26.3 million.

Previous wording

Net cash provided by financing activities was $7.7 million for the three months ended March 31, 2024 related to proceeds from stock option exercises.

Current wording

Net cash provided by financing activities was $8.3 million for the six months ended June 30, 2024 related to proceeds from stock option exercises.

Previous wording

In 2022, the Board approved a stock repurchase program of up to $500.0 million. In the first quarter of 2025, the Board approved an increase of $600.0 million to the Company’s stock repurchase program bringing the total repurchase authorization up to $1.1 billion. During the three months ended March 31, 2025, the Company repurchased 1,193,011 shares for $389.8 million. The Company did not execute any share repurchases during the three months ended March 31, 2024. As of March 31, 2025, the Company has remaining authorization of $344.8 million under the repurchase program.

Current wording

In 2022, the Company’s Board of Directors (“Board”) approved a stock repurchase program of up to $500.0 million. In the first and second quarters of 2025, the Board approved increases of $600.0 million and $1.0 billion, respectively, to the Company’s stock repurchase program bringing the total repurchase authorization up to $2.1 billion. During the three and six months ended June 30, 2025, the Company repurchased 1,754,264 shares and 2,947,275 shares for $518.5 million and